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New mode-of-action insecticides are sought to provide continued control of pesticide resis-
tant arthropod vectors of neglected tropical diseases (NTDs). We previously identified an-
tagonists of the AaDOP2 D1-like dopamine receptor (DAR) from the yellow fever mosquito,
Aedes aegypti, with toxicity to Ae. aegypti larvae as leads for novel insecticides. To extend
DAR-based insecticide discovery, we evaluated the molecular and pharmacological char-
acteristics of an orthologous DAR target, CqDOP2, from Culex quinquefasciatus, the vector
of lymphatic filariasis and West Nile virus.
Methods/Results
CqDOP2 has 94.7% amino acid identity to AaDOP2 and 28.3% identity to the human D1-
like DAR, hD1. CqDOP2 and AaDOP2 exhibited similar pharmacological responses to bio-
genic amines and DAR antagonists in cell-based assays. The antagonists amitriptyline,
amperozide, asenapine, chlorpromazine and doxepin were between 35 to 227-fold more
selective at inhibiting the response of CqDOP2 and AaDOP2 in comparison to hD1. Antago-
nists were toxic to both C. quinquefasciatus and Ae. aegypti larvae, with LC50 values rang-
ing from 41 to 208 μM 72 h post-exposure. Orthologous DOP2 receptors identified from the
African malaria mosquito, Anopheles gambiae, the sand fly, Phlebotomus papatasi and the
tsetse fly,Glossina morsitans, had high sequence similarity to CqDOP2 and AaDOP2.
Conclusions
DAR antagonists represent a putative new insecticide class with activity against C. quin-
quefasciatus and Ae. aegypti, the two most important mosquito vectors of NTDs. There has
been limited change in the sequence and pharmacological properties of the DOP2 DARs of
these species since divergence of the tribes Culicini and Aedini. We identified antagonists
selective for mosquito versus human DARs and observed a correlation between DAR phar-
macology and the in vivo larval toxicity of antagonists. These data demonstrate that
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sequence similarity can be predictive of target potential. On this basis, we propose expand-
ed insecticide discovery around orthologous DOP2 targets from additional dipteran vectors.
Author Summary
New mode-of-action insecticides are required to control arthropod vectors of neglected
tropical diseases (NTDs). Rational drug design approaches offer attractive methods to
identify new insecticidal chemistries that are potent and selective for molecular targets of
arthropod vectors. Previously identified antagonists of a D1-like dopamine receptor
(DAR) from the yellow fever mosquito, Aedes aegypti were toxic to the larvae of this spe-
cies and are candidate novel insecticide leads. Building on this work, here we evaluated the
molecular and pharmacological characteristics of an orthologous DAR from Culex quin-
quefasciatus, the vector of lymphatic filariasis and West Nile virus. We show that ortholo-
gous mosquito DARs have similar pharmacological profiles in vitro and that Ae. aegypti-
active DAR antagonists are toxic to C. quinquefasciatus larvae in vivo. Sequence similarity
between orthologous targets can be indicative of DAR target potential for discovery of po-
tent, selective inhibitors. These findings justify expansion of insecticide discovery efforts to
orthologous DARs from additional dipteran vectors of NTDs and provide support for
DAR antagonists as a new class of chemistries for taxon-selective insecticides for
vector control.
Introduction
Arthropod vectors transmit six of the 17 neglected tropical diseases (NTDs) currently recog-
nized by theWorld Health Organization (WHO). Of these, the causative agents of dengue virus
and lymphatic filariasis are transmitted by mosquitoes in the subfamily Culicinae (Phylum
Arthropoda; Class Insecta; Family Culicidae) and exact an enormous burden on human health
in tropical and subtropical regions of the globe. Aedes aegypti is the principal vector of dengue,
chikungunya, and yellow fever viruses, and Culex quinquefasciatus is the vector of West Nile
virus and the nematodeWuchereria bancrofti, the causative agent of lymphatic filariasis. An es-
timated 50–100 million dengue infections occur annually [1] and approximately 120 million
people are infected withW. bancrofti [2] with additional billions at risk of contracting these and
other mosquito-borne diseases. Chikungunya is an ongoing threat in Africa and Southern Asia,
and a recent outbreak could potentially lead to its establishment in the Americas [3].
The WHO has established a roadmap to eradicate multiple NTDs by 2020, backed by the
London Declaration on Neglected Tropical Diseases [4, 5]. Achievement of this goal will re-
quire a multi-pronged, integrated approach involving new and existing vector control strate-
gies, medicines, vaccines, and community outreach. Conventional insecticides will remain an
important foundation of programs aimed at the control, elimination, and eradication of NTDs.
Unfortunately the widespread development of insecticide resistant insect populations threatens
continued control [6]. Vector control currently relies on a limited repertoire of active ingredi-
ents and the issue of insecticide cross-resistance is compounded by the fact that no new insecti-
cides for insect vectors have become available for several decades [7]. In response, the
Innovative Vector Control Consortium (IVCC) issued a call for three new insecticides with
novel modes of action by 2023 to control malaria mosquitoes [8; http://www.ivcc.com]. The
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search for chemistries with unique and pest-specific modes of action with limited environmen-
tal impact necessitates new, rational design approaches [9].
G protein-coupled receptors (GPCRs) are successful pharmaceutical targets with over one
third of human drugs acting on these receptors or their downstream signaling processes [10].
Invertebrate GPCRs have long been suggested as targets for the development of new classes of
insecticides [11, 12]. The Purdue Insecticide Discovery Pipeline (PIDP) [13] is a GPCR-based
platform established for discovery and development of novel mode-of-action insecticides for
vector control [11, 13, 14, 15]. Initially the PIDP is pursuing small molecule antagonists and ag-
onists of invertebrate dopamine receptors (DARs) (Fig. 1) and has demonstrated proof of con-
cept in the Ae. aegypti DAR system [11, 13]. Vertebrate and invertebrate DARs are biogenic
amine receptors in the Class A rhodopsin-like subfamily of GPCRs. DARs have been implicat-
ed in several neurological diseases of humans such as Parkinson's disease and schizophrenia.
Scientific investment in human DAR pharmacology and associated therapeutic interventions
[16, 17] provides a much needed foundation to drive equivalent discovery work in
arthropod systems.
Dopamine has a role in locomotion, learning, courtship, development, and several other
complex behaviors in invertebrates [see 18, 19, and 11 for an overview]. Several studies suggest
that interference with dopaminergic processes may cause insect death or result in a variety of
phenotypes such as incapacitation and disrupted development [11, 13, 15, 20, 21] that are high-
ly attractive for insecticide development. The rational design of invertebrate DAR- and other
GPCR-targeting chemistries could generate highly effective molecules for vector control. Inver-
tebrates typically possess two D1-like receptors (Gαs coupled) and a single D2-like receptor
(Gαi/o coupled) [19, 22]. One of the D1-like DARs, hereafter referred to as DOP2, exhibits high
amino acid sequence identity among the arthropods Ae. aegypti, Anopheles gambiae (African
malaria mosquito), C. quinquefasciatus (northern house mosquito), Ixodes scapularis (Lyme
disease tick), Drosophila melanogaster (fruit fly), and Apis mellifera (honey bee) across the
transmembrane (TM) spanning domains (>70%) but limited sequence identity to the human
D1-like DARs, hD1 and hD5 (<55%) [13]. Two D1-like DAR sequences, AaDOP1 and
AaDOP2, were identified in the genome of the yellow fever mosquito, Ae. aegypti [23]. Assays
using AaDOP1 or AaDOP2 expressing cells revealed elevated cAMP levels following exposure
to dopamine in a concentration-dependent manner, providing support for the classification of
these receptors [11]. Subsequently, the discovery of receptor antagonists with mosquitocidal
properties was demonstrated by screening chemical libraries for AaDOP2 antagonists in cell-
based assays [11, 13]. Antagonists were evaluated in hit-to-lead studies that showed multiple
compounds were selective for the AaDOP2 target versus hD1 and caused rapid and high mor-
tality of Ae. aegypti larvae in vivo.
Two D1-like DARs, CqDOP1 and CqDOP2 were identified from the assembled genome of
C. quinquefasciatus [24] with CqDOP2 identified as the ortholog to AaDOP2 on the basis of
amino acid similarity [13]. AaDOP2 and CqDOP2 provide an opportunity to address questions
of relevance to insecticide discovery, namely (1) does sequence similarity between orthologous
targets equate to conservation of pharmacological properties in vitro, (2) is sequence similarity
predictive of the toxicity of target inhibitors in vivo, and (3) can differences in sequence be-
tween targets be exploited for development of taxon-selective chemistries? Here we present the
first study to assess conservation in the molecular and pharmacological properties of ortholo-
gous dopamine receptors from species representing two of the most important mosquito gen-
era affecting human health, Culex and Aedes. The human receptor, hD1, was evaluated in
parallel to determine the relative potency and selectivity of DAR antagonists for mosquitoes
versus humans. AaDOP2 antagonists were evaluated for toxicity to larvae of C. quinquefascia-
tus to explore the potential of extending the DAR antagonist-based insecticide discovery
Dopamine Receptor Antagonists as New Vector Insecticides
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approach to this vector. Lastly, in silico analyses were conducted to evaluate DOP2 targets from
three additional dipteran vectors of NTDs for inclusion in the PIDP; the An. gambiaemosqui-
to, a vector of malaria, the Phlebotomus papatasi sand fly vector of leishmaniasis, and the Glos-
sina morsitans tsetse fly vector of Human African Trypanosomiasis (sleeping sickness).
Methods
Mosquito culture
Mosquito larvae of the Liverpool strain IB12 of Ae. aegypti and the Johannesburg strain of C.
quinquefasciatus were reared in an insectary on a 12 h day/night cycle at 75% RH at 28°C in 25
Fig 1. Schematic depicting PIDP activities aimed at discovery of D1-like DAR antagonists as new
insecticides. The workflow is based on the evolving “genome-to-lead” component of the PIDP first described
in Meyer et al. [11]. High-throughput (HTP), cell-based screens expressing arthropod D1-like DARs (Target
Panel) are employed to identify chemistries active against one or more arthropod targets. Vector-selective
chemistries are identified using counter screens expressing the human hD1–5 and the honeybee DAR (Non-
target Panel). Subsequently, the in vivo toxicity of chemistries is confirmed in single-point dose and
concentration response screens against mosquito larvae. Top hits are evaluated for activity against the adult
stage of one or more vector species and taxon-level selectivity for the dipteran suborders Nematocera and
Brachycera, and the subclass Acari. Information from structure activity relationship studies is used to direct
iterative chemical screens. Chemical leads may enter the “Lead-to-Product” phase of the pipeline. New
components of the pipeline described in the present study include the pharmacologically characterized
CqDOP2 target, the AgDOP2, PpDOP2 andGmDOP2 targets identified from assembled genome sequences
(S2 Fig), and theC. quinquefasciatus larval screen. Remaining components are the subject of works in
review [15] and ongoing efforts. Abbreviations: Aa, Aedes aegypti; Ag, Anopheles gambiae; Am, Apis
mellifera; Cq, Culex quinquefasciatus; Gm,Glossina morsitans; Is, Ixodes scapularis; Pp, Phlebotomus
papatasi; NP, natural product.
doi:10.1371/journal.pntd.0003515.g001
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x 40 cm plastic pans (150 larvae per pan) on hamster pellets (Ae. aegypti) or ground flake fish
food (C. quinquefasciatus). Adult Ae. aegypti and C. quinquefasciatus that eclosed under this
rearing regimen had an average wing length of 3.4 mm (measured as in [25]) and 3.2 mm
(measured as in [26]), respectively, suggesting diet was sufficient and larval crowding effects
were minimal.
CqDOP2 receptor sequence and molecular characterization
The amino acid sequences of DARs from multiple arthropods were used to search the C. quin-
quefasciatus genome using the Basic Local Alignment Search Tool (tBLASTn, [27]). Gene
models were confirmed by sequencing of amplified RT-PCR products following procedures de-
scribed in Meyer et al [11]. Briefly, total RNA was extracted from adult C. quinquefasciatus fe-
males and treated with RNase-free DNase. RT-PCR amplification was performed using the
SuperScript One-Step RT-PCR kit (Invitrogen, Carlsbad, CA) and the CqDOP2-specific prim-
ers CqDOP2_1F: 5'-ATGATGACTACGAATGCAACTGATTAC-3' and CqDOP2_1R: 5'-
CTAAATGTACGTCTGCTCGCAC-3'. RT-PCR products separated by electrophoresis on a
1% agarose gel were excised and cloned using the TOPO TA cloning kit (Invitrogen, Carlsbad,
CA). Purified plasmids from the resulting clones were sequenced at the Purdue Genomics Core
Facility (PGFC). DNA sequences were used to predict full-length coding regions and manual
annotation was performed using Artemis software (version 9) [28]. The CqDOP2 conceptual
protein sequence was aligned to that of AaDOP2 using ClustalW [29] and used to identify con-
served amino acid residues and predict protein structural features [22, 30, 31].
To determine receptor expression in different life stages, total RNA was isolated from C.
quinquefasciatus eggs, L4 larvae, pupae, and 5-day old adults (female and male) using the
RNeasy Mini Kit (Qiagen) and following kit protocols, including DNase treatment. Generation
of cDNA was performed using the iScript cDNA Synthesis Kit (Bio-Rad). Reverse transcription
polymerase chain reaction (RT-PCR) was used with cDNA template, primers CqDOP2_1F
and CqDOP2.2R: 5'-CCAGCAGTGGAAGATAGAACG-3', Taq polymerase (Phusion, New
England Biolabs) and the following thermo-cycling conditions: 35 cycles at 94°C, 45 s; 55°C, 45
s; 72°C, 2 min. Subsequent products were separated by gel electrophoresis and photographed
(EpiChemi II Darkroom, UVP Laboratory Products). Products of approximately 700 bp in
length were excised, purified (MinElute Gel Extraction Kit, Qiagen), and sequenced at the
PGCF.
A neighbor-joining phylogenetic analysis was conducted using amino acid sequences of ar-
thropod and mammalian GPCRs retrieved from GenBank. MEGA6 [32] was used to align and
perform tree construction according to the procedure of Hall [33]. Diuretic hormone 44 recep-
tor 1 (D.melanogaster) was used as an outgroup. Bootstrap analysis (1000 replicates) was per-
formed as an estimate of branch reliability.
In silico assessment of DOP2 DAR targets from additional dipteran
vectors of NTDs
To assess the potential of expanding the PIDP pipeline to orthologous DOP2 targets from a
range of key dipteran vectors, additional tBLASTn searches of the assembled genomes of An.
gambiae, P. papatasi (www.vectorbase.org) and G.morsitans [34] were performed using
AaDOP2 and CqDOP2 sequences. The conceptual amino acid sequences for the resultant gene
models, AgDOP2, PpDOP2, and GmDOP2, were aligned with AaDOP2 and CqDOP2 using
ClustalW [29] and conserved structural features were predicted as described above.
Dopamine Receptor Antagonists as New Vector Insecticides
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Pharmacological characterization of CqDOP2 and AaDOP2
For functional characterization of the mosquito receptors, CqDOP2 and AaDOP2 were synthe-
sized by Genscript (Piscataway, NJ) and cloned into the expression vector pcDNA3.1+ (Invitro-
gen, Carlsbad, CA). Stable cell lines expressing the receptors in HEK293 cells were generated as
described previously for AaDOP2 [11]. The AaDOP2 expressing cells used here were from the
same clone previously utilized for AaDOP2 characterization [11]. Briefly, HEK293-CRELuc cells
were plated in Dulbecco's modified eagle's medium (DMEM) supplemented with 5% bovine calf
serum, 5% fetal clone I (Thermo Scientific, WalthamMA), 1% Antibiotic-Antimycotic (Life
Technologies, Grand Island NY) and 2 μg/ml puromycin (Sigma-Aldrich, St. Louis, MO), trans-
fected, and then subjected to selection with G418 (600 μg/ml). G418-resistant clones were select-
ed and screened for receptor expression in the cAMP activated luciferase (CRELuc) reporter cell
line construct [11]. For pharmacological characterization of receptor activity, cryopreserved cells
stably expressing AaDOP2 (10,000 cells/well), CqDOP2 (5,000 cells/well), or human D1 (5,000
cells/well) were thawed, washed, and re-suspended in assay buffer (Hank’s balanced salt solution,
Hyclone, Logan, UT) supplemented with 20 mM 2-[4-(2-hydroxyethyl)piperazin-1-yl]ethane-
sulfonic acid (HEPES, Hyclone, Logan, UT) and 0.1% bovine serum albumin (MP Biomedicals,
Santa Ana, CA), seeded in white 384 well plates (PerkinElmer, Waltham, MA), and incubated
for 1 h at 37°C. Compounds were serially diluted in assay buffer containing 3-isobutyl-
1-methylxanthine (IBMX, final concentration 0.5 mM), added to the plates, and incubated for
1 h at 25°C to allow for cAMP accumulation. Reactions were stopped and cAMP was measured
by a homologous time-resolved fluorescence (HTRF) assay according to the manufacturer’s rec-
ommendations (Cisbio, Bedford, MA). Fluorescence was read on a Synergy4 plate reader (Bio-
Tek, Winooski, VT).
Dopamine hydrochloride, histamine dihydrochloride, 5-hydroxytryptamine hydrochloride
(serotonin), (±)-octopamine hydrochloride, tyramine hydrochloride (Sigma-Aldrich, St. Louis,
MO), (-)-epinephrine bitartrate, and L (-)-norepinephrine bitartrate (Research Biochemical In-
ternational, Natick, MA) were used for initial receptor characterization studies. Antagonist
profiles were generated by adding serially diluted antagonists followed by dopamine (3 μM for
AaDOP2- and CqDOP2-, and 0.5 μM for hD1-expressing cells). The antagonists amitriptyline
hydrochloride, asenapine maleate, (±) butaclamol hydrochloride, chlorpromazine hydrochlo-
ride, doxepin hydrochloride, cis-(Z)-flupenthixol dihydrochloride, SCH23390 hydrochloride
(Sigma-Aldrich, St. Louis, MO), and amperozide hydrochloride (Tocris bioscience, Ellisville,
MO) were selected based on previous chemical screens against AaDOP2 and subsequent bioas-
says against Ae. aegypti larvae [11, 13]. All serial dilutions were carried out using the Precision
liquid handling station (BioTek, Winooski, VT). Data were collected from a minimum of three
independent experiments conducted in duplicate. Statistical analysis of data was conducted
with GraphPad Prism 6 software (GraphPad Software Inc., San Diego, CA).
In vivo C. quinquefasciatus and Ae. aegypti bioassays
A panel of nine AaDOP2 antagonists was selected based on toxicity determined from single-
point dose, high-throughput screens against Ae. aegypti larvae [13, 15]. Compounds were eval-
uated in parallel in concentration-response assays against third-instar larvae (L3) of C. quin-
quefasciatus and Ae. aegypti at room temperature (23–25°C). Larvae were transferred using a
plastic pipette to the wells of a 24-well tissue culture plate (Corning Inc., Corning NY) (five lar-
vae per well) containing 1 ml de-ionized water and 400, 200, 100, 50, or 25 μM test compound
or water only as the control. Antagonists were diluted in water to the desired concentration im-
mediately before transfer to tissue culture plates. Larval mortality was determined every 30 min
for the first 3 h, then daily at 24, 48, and 72 h post-exposure. Plates were gently shaken and
Dopamine Receptor Antagonists as New Vector Insecticides
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larvae were lightly touched with a sterile probe (up to three times, as required) and stringent
criteria were established for scoring such that larvae that failed to respond to both stimuli were
recorded as dead. Four technical replicates were performed per dose, and each bioassay was
performed a minimum of three times. Calculations of lethal concentration 50 (LC50) and lethal
time 50 (LT50) were made using GraphPad Prism 6 software (GraphPad Software Inc., San
Diego, CA).
Results
CqDOP2 receptor sequence and molecular characterization
A 1,440 bp sequence encoding the predicted open reading frame of CqDOP2 was identified
from cloned RT-PCR products (Genbank ID KM262648). Alignment of the conceptual
CqDOP2 amino acid sequence with that of AaDOP2 showed high overall amino acid sequence
identity (94.7%) and 100% identity in the predicted TM-spanning domains (Fig. 2). The great-
est divergence between the two sequences was observed in the third intracellular loop (ILIII)
with nine amino acid differences and two additional amino acids in CqDOP2, and in the N-ter-
minus with seven differences, and two additional amino acids in CqDOP2 and one additional
residue in AaDOP2. The remaining amino acid differences were primarily conservative
Fig 2. Alignment ofCqDOP2 and AaDOP2 amino acid sequences. Highlighted areas indicate identical and conserved residues as designated by
ClustalW [29]: black = identical residues; dark gray = strongly similar residues; light gray = weakly similar residues (for amino acid similarity groups, see:
http://www.clustal.org/download/clustalx_help.html). Putative transmembrane (TM) domains I-VII are indicated as a line above the alignment.
doi:10.1371/journal.pntd.0003515.g002
Dopamine Receptor Antagonists as New Vector Insecticides
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substitutions. CqDOP2 possesses key biochemical features considered essential for GPCR func-
tion and that were also identified in AaDOP2 (Table 1). Residues D140, S225, and S228 of
CqDOP2 are predicted to interact directly with biogenic amines [19] while the "DRY" motif
(residues 157–159), and aspartate in TMII (D105) are required for receptor activation.
CqDOP2 also possesses several putative palmitoylation and phosphorylation sites. Sequences
from ~700 bp RT-PCR products amplified from C. quinquefasciatus eggs, L4 larvae, pupae or
adult male or female cDNA (S1 Fig) matched that of the expected region of CqDOP2, confirm-
ing the presence of CqDOP2 transcripts in the life stages examined.
Neighbor-joining sequence analysis (Fig. 3) placed CqDOP2 in a clade with other inverte-
brate D1-like DOP2 receptors from Ae. aegypti (AaDOP2), Ap.mellifera (AmDOP2), B.mori
(BmDOPR2), D.melanogaster (DmDAMB), and I. scapularis (IsDOP2). This group formed
part of a larger clade comprising invertebrate octopamine receptors (DmOAMB, BmOAR1,
and AmOA1), but not human DARs. The analysis also revealed a second cluster comprising
other invertebrate D1-like receptors, including IsDOP1, AmDOP1, BmDOPR1, DmD-DOP1,
and AaDOP1 and the human DARs, hD1 and hD5. The invertebrate D2-like receptor sequences
from Ap.mellifera (AmDOP3), B.mori (BmDOPR3), and D.melanogaster (DmDD2R) were
placed in a cluster with CqDOP3 and AaDOP3 and formed part of a larger clade with the
human D2-like receptors hD2, hD3, and hD4.
Table 1. Comparison of protein features forCqDOP2 and AaDOP2.
Protein features CqDOP2 AaDOP2a
Total length 479 476
Length of N-terminusb 58 57
Length of intracellular loops I, II, IIIb 10, 20, 117 10, 20, 115
Length of extracellular loops I, II, IIIb 15, 18, 9 15, 18, 9
Length of carboxyl tailb 63 63
1–4 N-linked glycosylation sites (N-terminus) N5, N21, N26, N47 N3, N19, N24, N46
Conserved cysteines in extracellular loops
1–2c
C133, C212 C132, C211
C-terminus palmitoylation sites (C) C387, C431, C432, C457 C384, C428, C429, C454
Protein kinase A/C phosphorylation
(Intracellular loops II, III and C-terminus)
S167, T173, T251, S253, T279, T307, S342, S344,
T443, S449, S454, S459, T460, S462, S473
S166, T172, T250, S252, T278, T305, S339, S341,
T440, S446, S451, S456, T457, S459, S470
Conserved aspartates in TMII, TMIIId D105, D140 D104, D139
Conserved “DRY” motife D157, R158, Y159 D156, R157, Y158
Conserved serines in TMVf S224, S225, S228 S223, S224, S227
Conserved aromatic residue in TMVg F229 F228
Conserved aromatic residues in TMVIg W371, F374, F375 W368, F371, F372
The number of amino acids composing the N- and C-termini and the intracellular and extracellular loops are relative to the transmembrane domain (TM)
sequences shown in Fig. 2.
aAaDOP2 features from [11]
bValues refer to the number of amino acids composing these features
cPresumed to form a disulfide bond for protein stabilization
dPredicted as important for binding the amine moieties of catecholamines
eImplicated in G-protein coupling
fPredicted to form hydrogen bonds with catechol hydroxyl groups
gAromatic residues implicated in ligand interaction
doi:10.1371/journal.pntd.0003515.t001
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Fig 3. Neighbor-joining sequence analysis ofCqDOP2, AaDOP2 and representative biogenic amine
receptors. Abbreviations and NCBI accession numbers of species indicated are as follows: Aedes aegypti =
Aa; AaDOP1 = D1-like dopamine receptor 1 (JN043502); AaDOP2 = D1-like dopamine receptor 2
(JN043503); AaDOP3 = D2-like dopamine receptor (XM_001648573);Culex quinquefasciatus = Cq;
CqDOP1 = D1-like dopamine receptor 1 (XM_001842358); CqDOP2 = D1-like dopamine receptor 2
(KM262648); CqDOP3 = D2-like dopamine receptor (XM_001865540); Ixodes scapularis = Is; IsDOP1 = D1-
like dopamine receptor 1 (ISCW001496); IsDOP2 = D1-like dopamine receptor 2 (ISCW008775); D.
melanogaster = Dm; DmD-Dop1 = D1-like dopamine receptor (P41596); DmDAMB = D1-like dopamine
receptor (DopR99B/DAMB: AAC47161); DmDD2R = D2-like dopamine receptor (DD2R-606: AAN15955);
DmDih = diuretic hormone 44 receptor 1 (NP_610960.1); DmmAChR = muscarinic acetylcholine receptor
(AAA28676); DmOAMB = octopamine receptor in mushroom bodies, isoform A (NP_732541);
Dm5HT1A = serotonin receptor 1A, isoform A (AAM68432); DmTyr = tyramine receptor (CG7431:
NP_650652); Apis mellifera = Am; AmDOP1 = D1-like dopamine receptor (NP_001011595); AmDOP2 = D1-
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In silico assessment of DOP2 DAR targets from additional dipteran
vectors of NTDs
Sequences containing putative DOP2 coding regions were identified from An. gambiae
(AgDOP2), P. papatasi (PpDOP2), and G.morsitans (GmDOP2) using tBLASTn searches. Per-
centage identity of amino acid sequences relative to AaDOP2 were as follows:
AgDOP2 = 82.6%; PpDOP2 = 81.3%; GmDOP2 = 79.0%. Alignment revealed preservation of
aspartate and serine residues predicted to bind biogenic amines and key aspartate residues and
the DRY motif required for receptor activation (S2 Fig). Putative palmitoylation and phosphor-
ylation sites were also preserved with the exception of residue K426 in P. papatasi. Amino acid
sequences were most divergent between species in the N-terminus and in ILIII.
Pharmacological characterization of CqDOP2 and AaDOP2
Although we have previously reported partial characterization of AaDOP2 using a luciferase-
based system [11], we evaluated CqDOP2 and AaDOP2 here in parallel using a HTRF-based
cAMP assay (Cisbio, Bedford, MA) to avoid assay-induced bias. Both CqDOP2 and AaDOP2
responded to dopamine, with EC50 values of 2.3 and 1.7 μM, respectively (Fig. 4). For both re-
ceptors, epinephrine and norepinephrine elicited an increase in cAMP, however, these biogenic
amines were much less potent having EC50 values at least 10-fold higher than that of dopamine
(Table 2). Treatment with histamine, octopamine, serotonin, or tyramine did not cause a mea-
surable response in activity for either receptor.
like dopamine receptor (NP_001011567); AmDOP3 = D2-like dopamine receptor (NP_001014983);
AmmAChR = muscarinic acetylcholine receptor (XP_395760); AmOA1 = octopamine receptor (oar,
NP_001011565); Am5HT1A = serotonin receptor (NP_001164579); AmTyr = tyramine receptor
(NP_001032395.1); Bombyx mori = Bm; BmDOPR1 = D1-like dopamine receptor (AB162715);
BmDOPR2 = D1-like dopamine receptor (AB162716); BmDOP3 = D2-like dopamine receptor
(XM_004925908); BmmAChR = muscarinic acetylcholine receptor (XM_004922849);
BmOAR1 = octopamine receptor (NM_001098278); Bm5HTR = serotonin receptor (X95604);
BmTAR2 = tyramine receptor (NM_001171178); Homo sapiens = h; hD1, D1-like dopamine receptor (D(1A),
NP_000785); hD2 = D2-like dopamine receptor (D(2), NP_000786); hD3 = D2-like dopamine receptor (D(3),
NP_000787); hD4 = D2-like dopamine receptor (D(4), NP_000788); hD5 = D1-like dopamine receptor (D(1B)/
D5,NP_000789). * Indicates receptors pharmacologically characterized in the current study.
doi:10.1371/journal.pntd.0003515.g003
Fig 4. Pharmacological characterization of AaDOP2 andCqDOP2 stably expressed in HEK293 cells.
Normalized cAMP response (mean ± SEM) seen as a function of concentration of dopamine, norepinephrine,
and epinephrine for each receptor. The graphs are based on the compiled data (n 8 independent
experiments, conducted in duplicate) and normalized using GraphPad Prism software to the maximal
dopamine response for each experiment.
doi:10.1371/journal.pntd.0003515.g004
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The dopamine-stimulated activity of CqDOP2 and AaDOP2 in response to a subset of
AaDOP2 and hD1 antagonists mirrored each other, but differed from those observed for hD1
(Fig. 5, Table 3). Amitriptyline, asenapine, amperozide, chlorpromazine, and doxepin were
markedly more potent at both mosquito receptors over the human receptor. In contrast, the D1
antagonists (±) butaclamol and SCH23390 were approximately 60-fold and 500-fold more se-
lective for the human receptor over the mosquito receptors, respectively.
In vivo C. quinquefasciatus and Ae. aegypti bioassays
To test the in vivo activity of select antagonists, concentration-response assays were conducted
against L3 larvae of C. quinquefasciatus and Ae. aegypti. All DAR antagonists elicited70%
mortality of Ae. aegypti and C. quinquefasciatus larvae by 72 h at 400 μM, the highest dose test-
ed (Fig. 6). The LC50 values at 72 h ranged from 41 to 208 μM depending on antagonist and
mosquito species (Table 4). Chlorprothixene was the most toxic compound, eliciting the lowest
LC50 values in both species (41±7 μM for C. quinquefasciatus and 62±9 μM for Ae. aegypti)
and the lowest LT50 values (13.9±2.0 h for C. quinquefasciatus and 22.2±3.2 h for Ae. aegypti)
(Table 4). Mortality to antagonists in both species was similar, although C. quinquefasciatus
larvae were slightly more susceptible than Ae. aegypti larvae, having lower LT50 and LC50 values
(Fig. 6, Table 4). Four compounds (chlorprothixene, chlorpromazine, methiothepin, and mian-
serin) caused>70% mortality in C. quinquefasciatus within the first 24 h (S3 Fig), and all but
amitriptyline caused>70% mortality by 48 h (S4 Fig). In Ae. aegypti,>70% mortality was ob-
served after 48 h for five compounds (chlorprothixene, chlorpromazine, methiothepin, mian-
serin, and asenapine) (S4 Fig).
Discussion
The sequence identity (94.7%, Fig. 2), key structural features (Table 1), and pharmacological
profile (Figs. 4–5, Tables 2–3) of CqDOP2 identify this receptor as the ortholog of AaDOP2
(Figs. 2, 3). The detection of CqDOP2 (S1 Fig) and AaDOP2 transcripts [11] in all life stages
examined suggests these receptors are constitutively expressed and likely regulate essential,
conserved functions throughout the insects' life cycle. The 24 amino acid substitutions (the ma-
jority of which are conservative), additions, or deletions between the two sequences (Fig. 2)
provided an opportunity to assess impact of these residues on DAR pharmacology. The similar
pharmacological profiles of CqDOP2 and AaDOP2 suggest that the 24 residues in question do
not greatly affect receptor interaction with either dopamine or a variety of antagonists. DOP2
was likely present in the common ancestor of modern mosquitoes and ticks as all invertebrate
D1-like DOP2 sequences clustered together in the neighbor-joining analysis (Fig. 3). The over-
all amino acid identity of DOP2 DARs from An. gambiae, P. papatasi and G.morsitans relative
to AaDOP2 decreased as taxonomic distance increased between the subfamily Culicinae and
Table 2. EC50 values (μM±SEM) for dopamine and other biogenic amines estimated from concentra-
tion response curvesmeasuring the cAMP response from HEK293 cells expressing AaDOP2 or





No response was observed for histamine, octopamine, serotonin, or tyramine for concentrations up to
100 μM.
doi:10.1371/journal.pntd.0003515.t002
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the subfamily Anophelinae (AgDOP2, 82.6%), and the dipteran suborders Nematocera
(PpDOP2, 81.3%) and Cyclorrhapha (GmDOP2, 79.0%). The pharmacological characterization
of these receptors (S2 Fig), together with published data for IsDOP2 from the tick, I. scapularis
(Fig. 1) [14, 22], will contribute to an understanding of how progressively greater changes in
Fig 5. Characterization of select antagonists on receptor activity in HEK cells stably expressing
CqDOP (), AaDOP2 (●), or the human D1 receptor (■).Graphs are based on compiled cAMP
measurements (n 3 independent experiments) normalized using GraphPad Prism software to the
dopamine response for each experiment and shown as mean ± SEM.
doi:10.1371/journal.pntd.0003515.g005
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amino acid sequence influence pharmacology between DARs from arthropod vectors of
divergent lineages.
CqDOP2 was pharmacologically distinguished as a D1-like dopamine receptor through het-
erologous expression experiments that showed concentration-dependent increases in cAMP
production in response to dopamine. Responses were also elicited by epinephrine and norepi-
nephirine but over 10-fold more agonist was required to reach maximum stimulation of cAMP
in comparison to dopamine (Fig. 4, Table 2). CqDOP2 displayed a similar pharmacological
profile to AaDOP2 in the presence of dopamine, epinephrine, and norepinephirine, suggesting
that the dopaminergic ligand binding pocket and receptor activation have been conserved
Table 3. IC50 values (nM±SEM) for inhibition of dopamine-stimulated cAMP response in HEK293 cell lines by DAR antagonists.
AaDOP2 CqDOP2 Human D1 Fold selectivity to Human D1
AaDOP2 CqDOP2
Amitriptyline 6.4±2 3.3±0.4 690±52 108 209
Amperozide 469±71 248±42 16200±4770 35 65
Asenapine 0.7±0.2 0.8±0.03 101±2 144 126
(±)-Butaclamol 226±36 172±15 2.8±0.5 0.012 0.016
Chlorpromazine 19±1 7.4±2 972±160 51 131
Cis-(Z)-flupenthixol 2±0.8 2±0.5 9.4±3 5 5
Doxepin 17±4 8.3±0.6 1890±455 111 227
SCH23390 709±187 745±62 1.6±0.2 0.002 0.002
Values were determined from concentration response curves measuring the cAMP response. Fold selectivity was determined by dividing human D1 IC50
values by each respective mosquito DOP2 IC50 value for each antagonist.
doi:10.1371/journal.pntd.0003515.t003
Fig 6. Concentration response curves forC. quinquefasciatus () and Ae. aegypti (●) showing percent
larval mortality at 72 h post exposure to DOP2 antagonists. Each data point represents mean ± SEM
(n 3 independent experiments).
doi:10.1371/journal.pntd.0003515.g006
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between these species. In Ap.mellifera, a response to norepinephirine was also noted for
AmDOP2, requiring approximately 25-fold more agonist than dopamine [19]. The D.melano-
gaster DOP2 ortholog, DmDAMB, also was modestly receptive to norepinephirine. Neither of
the mosquito receptors in the current study showed detectable cAMP production over basal in
response to histamine, serotonin, tyramine, or octopamine, a result similar to characterizations
of Ap.mellifera and D.melanogaster DOP2 receptors [19]. Slight discrepancies between dopa-
mine EC50 values for AaDOP2 in this study (2.3 ± 0.7 μM) and previous reports
(0.24 ± 0.16 μM) may reflect the different assay methods used; HTRF in the current study and
a luciferase-based reporter assay in Meyer et al. [11]. The HTRF assay directly measures cAMP
and offers enhanced accuracy over the indirect cAMP measurements of the luciferase assay
[15]. In addition, adoption of the HTRF assay into the PIDP (Fig. 1) is seen as a technical im-
provement for high throughput screening.
The response of CqDOP2 and AaDOP2 to antagonists was also similar (Fig. 5, Table 3). In
contrast, hD1 was much less sensitive to amitriptyline, asenapine, amperozide, chlorpromazine,
and doxepin and more sensitive to (±) butaclamol and SCH23390 than either mosquito receptor
(Table 3). This pharmacological evidence is in agreement with previous studies that show a struc-
tural and pharmacological distinction between the five human DARs and arthropod DOP2 re-
ceptors [19, 35]. The difference in activity between the mosquito and human receptors in our
study suggests antagonists could be developed with target activity for insect pests while remain-
ing safe for non-target organisms, although further testing is required. The response to cis-(Z)-
flupenthixol was similar across all three receptors (Fig. 5, Table 3) suggesting overlapping antago-
nist interactions between these divergent DARs. Cis-(Z)-flupenthixol has previously been noted
as a nonselective DAR antagonist in arthropods [19] highlighting the importance of counter
screening to avoid pursuit of leads with potential effects on non-target organisms (See Fig. 1).
Consistent with the findings of Meyer et al. [11] and Hill et al. [13], all DAR antagonists
were highly toxic to Ae. aegypti larvae in vivo, and demonstrated similar toxicity profiles
against C. quinquefasciatus larvae. This is the first report of DAR antagonist toxicity to the lat-
ter species. Larval assays revealed a similar rank order of DAR antagonist-induced mortality to
that observed for the potency of antagonists at CqDOP2 and AaDOP2 in vitro, with the excep-
tion of amitriptyline in both species and asenapine in Ae. aegypti. These results suggest that
small molecule DOP2 antagonist leads identified for either Ae. aegypti or C. quinquefasciatus
will likely be toxic to both species and that this toxicity is related to similarity in the pharmaco-
logical response of the DOP2 receptors. These leads may be more broadly effective against
Table 4. Lethal concentration (LC50) values (μM±SEM, 72 h exposure) and lethal time (LT50) values
(h±SEM at 400 μM), for AaDOP2 antagonists on larvae of C. quinquefasciatus (Cq) and Ae. aegypti
(Aa) (n 3).
LC50 LT50
Cq Aa Cq Aa
Amitriptyline 165±37 208±137 41.7±2.1 47.8±6.3
Amperozide 135±35 161±20 25.4±1.5 46.6±6.2
Asenapine 50±10 102±22 24.2±1.3 36.4±1.6
Chlorpromazine 64±9 88±9 16.7±1.1 26.1±0.9
Chlorprothixene 41±7 62±9 13.9±2.0 22.2±3.2
Cis-(Z)-flupenthixol 59±22 83±25 35.2±6.1 42.6±2.9
Clomipramine 89±19 88±24 27.3±3.0 28.7±3.1
Methiothepin 44±3 69±12 15.7±4.9 30.6±1.4
Mianserin 126±46 121±57 17.9±3.0 22.8±1.3
doi:10.1371/journal.pntd.0003515.t004
Dopamine Receptor Antagonists as New Vector Insecticides
PLOS Neglected Tropical Diseases | DOI:10.1371/journal.pntd.0003515 March 20, 2015 14 / 19
mosquito larvae, as amitriptyline also has been reported to have larvicidal properties against
An. gambiae [21].
In addition to mortality, sublethal effects of antagonists on larval behavior and development
were noted throughout the course of this study. Larvae were "debilitated" (i.e., slower and less
vigorous in their response to shaking of plates or touch with a sterile probe compared to con-
trol larvae) at high concentrations (400–200 μM) of all antagonists with the exception of clo-
mipramine. This was observed as early as 1 h after exposure in C. quinquefasciatus in response
to 400 μM chlorprothixene, methiothepin, or chlorpromazine and 2 h after exposure to chlor-
prothixene in Ae. aegypti. Molting to the L4 stage was common for control and treated larvae
throughout the experiment, yet the exuviae frequently remained attached to treated larvae, and
in particular to debilitated individuals (S5 Fig). Disruption of dopaminergic signaling may par-
tially explain the debilitated phenotype and the difficulty of larvae to completely free them-
selves from their exuviae as dopamine has a role in locomotion [18, 19]. In addition, a
"shortened" phenotype where larval length was reduced (S5 Fig) was noted in some treated lar-
vae (with the exception of amperozide, asenapine, and mianserin), typically occurring within
24 to 48 h after exposure and observed in both L3 and L4 stages. The link to dopamine signal-
ing with this phenotype is less clear and may relate to as yet uncharacterized functions of the
DOP2 receptor, or impacts on other receptor types (see below). Further quantitative studies
tracking antagonist effects throughout larval development could provide a more comprehen-
sive picture of their impact, and a closer focus on molting would be particularly interesting
given the role of dopamine in this process [20].
While the DAR antagonists investigated herein hold promise for rational insecticide design,
the mode of action responsible for in vivo toxicity remains uncharacterized. The remarkable
correlation between in vitro data and in vivo larval and adult data, confirmed by linear regres-
sion [15], and supported in the current study with C. quinquefasciatus, provides evidence for
activity of these compounds at CqDOP2 and AaDOP2 in vivo. Attempts to analyze receptor-
antagonist interaction in vivo via rescue of amitriptyline treated adult mosquitoes with co-
injection of dopamine by our group and others [21] have not proven successful to date. Several
studies suggest that some of the DAR antagonists employed in the current study may have ac-
tivity at other biogenic amine receptors that could result in a more complex pharmacological
response in vivo. For example, an interaction of methiothepin with serotonin receptors ex-
pressed in the Malpighian tubules of Ae. aegypti has been suggested by several studies [36, 37].
Mianserin and chlorpromazine are β-adrenergic-like octopamine receptor antagonists in the
moth Chilo suppressalis [38] and cis-(Z)-flupenthixol is an antagonist for an α-adrenergic-like
octopamine receptor in Ap.mellifera [39]. Amperozide and asenapine have not, to our knowl-
edge, been used in studies on insects and further investigation of these antagonists against a
range of biogenic-amine binding invertebrate GPCRs may yield insights into mode-of-action.
An insecticidal discovery approach that disrupts multiple arthropod receptors as has been pro-
posed in human pharmaceutics, i.e., the magic shotgun versus the magic bullet approach [40],
could be an attractive alternative to receptor-specific chemistries.
Improvements in potency and toxicity are typically achieved via medicinal and product for-
mulation chemistry, respectively. The antagonists tested here were unformulated for delivery.
Thus degradation, metabolic detoxification by insect enzymes as well as differences in penetra-
tion of the cuticle, gut lining, or neural tissue may limit bioavailability. Many of the principles
and approaches used in human pharmaceutical research to understand the absorption, distri-
bution, metabolism and excretion (ADME) of molecules could have application for DAR-
antagonist insecticide discovery. Improvement in compound delivery with the addition of car-
riers, synergists or through the use of analogs derived from these chemistries will ideally result
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in compounds capable of inducing toxicity at nM to pM concentration, a desired target range
for use of pesticides in the field.
The PIDP is a target-based pipeline for discovery of new mode-of-action insecticides
(Fig. 1) with initial proof of concept provided by studies of the D1-like DAR, AaDOP2 [11, 13,
15]. Here we show that the pharmacological properties of the orthologous target, CqDOP2,
from a second mosquito vector of NTDs, C. quinquefasciatus, largely mirror those of AaDOP2,
and that the toxicity of AaDOP2-active antagonist leads extends to the larvae of this species.
This study brings the number of pharmacologically characterized vector DOP2 DARs in the
PIDP to five: CqDOP2 (this study), AaDOP1 and 2 [11], IsDOP1 and 2 [14, 22] and extends
the activity of pipeline chemistries to a second taxonomic group of vectors in the subfamily
Culicinae. Three DOP2 targets, AgDOP2, PpDOP2, and GmDOP2 from the dipteran vectors
of malaria, leishmaniasis, and African Trypanosomiasis, and proposed counter-screens against
the honeybee DOP2 DAR will enable expansion in the scope and insecticide discovery poten-
tial of the PIDP. Larval mosquito assays offer a relatively inexpensive, high-throughput tool to
narrow down chemical leads for evaluation in more labor-intensive assays for activity against
adult vectors. Combined, these pipeline components enable the discovery of taxon-selective
chemistries and the early elimination of molecules with undesirable environmental impacts.
While the present study focused on D1-like DARs, in theory the PIDP could be applied to dis-
covery of agonists, and inhibitors of D2-like and other biogenic amine-binding receptors in the
search for GPCR-active, novel insecticides.
Summary and future work
This study provides evidence for CqDOP2 as a D1-like DAR and supports an orthologous rela-
tionship to AaDOP2. Within the mosquito subfamily Culicinae, tribes Aedini (including Ae.
aegypti) and Culicini (including C. quinquefasciatus) are thought to have diverged in the early
Cretaceous, an estimated 127 to 158 million years ago [41], yet the degree of sequence and
pharmacological similarity, coupled with the detection of transcripts in all life stages, suggests
that CqDOP2 and AaDOP2 play a conserved role in mosquito neurological processes and may
explain the similar toxic effects of DAR antagonists to the larvae of C. quinquefasciatus and Ae.
aegypti. These findings are an important step towards understanding the relationship between
sequence similarity, DAR pharmacology in vitro and antagonist toxicity in vivo. Future muta-
genesis and modeling work with these receptors may reveal key DAR structural features re-
quired for activity that may be used to predict the pharmacology of orthologous targets. This
information could be used to assess the value of de-orphanization and development of addi-
tional orthologous targets, which represents a considerable time and cost investment. DAR an-
tagonist toxicity to C. quinquefasciatus suggests these molecules may have activity against
other culicine species and possibly other arthropod vectors. The three additional DOP2 targets,
AgDOP2, PpDOP2 and GmDOP2, identified in this study (Figs. 1, S2) provide a powerful re-
search tool to investigate DAR antagonist potency to other dipteran vectors and the pharmaco-
logical consequences of divergence in amino acid sequences in these species. Importantly, our
finding that CqDOP2 and AaDOP2 are pharmacologically distinct from the human D1-like
DAR, hD1, and exhibit a 35 to 227-fold range difference in response to select antagonists sug-
gests that differences between mosquito and human DARs can be exploited for development of
mosquito-selective compounds with low mammalian toxicity.
The DAR antagonists tested in this study are tricyclic amines, with the exception of ampero-
zide, a diphenylbutylpiperazine. Modeling of mosquito receptors may allow prediction of li-
gand binding sites and facilitate directed searches for small molecule inhibitors, potentially
revealing new classes of DAR antagonists selective for mosquitoes. Agonists also have potential
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to disrupt AaDOP2 signaling [13] and should be examined against CqDOP2 and the DOP2
DAR targets of other dipteran vectors identified in this study. The rational, target-based insec-
ticide discovery approach taken in this study provides further evidence that investment in
small molecule antagonists of invertebrate GPCRs may deliver much needed novel mode-of-
action products to the vector control market.
Supporting Information
S1 Fig. Detection of CqDOP2 transcripts in C. quinquefasciatus life stages by end-point
RT-PCR. Abbreviations: E, egg; L, L4 larva; P, pupa; AF, adult female; AM, adult male.
(TIF)
S2 Fig. Alignment of DOP2 amino acid sequences from selected dipteran vectors of NTDs.
Black and gray highlighted areas indicate identical and conserved residues as designated by Clus-
talW [29]: black = identical residues; dark gray = strongly similar residues; light gray = weakly
similar residues (for amino acid similarity groups, see: http://www.clustal.org/download/
clustalx_help.html). Color coding indicates conserved structural features. Orange = residues re-
quired for receptor activation; Blue = biogenic amine interaction sites; Green = putative protein
kinase A/C phosphorylation sites; Yellow = putative palmitolyation sites. Putative transmem-
brane (TM) domains I-VII are indicated as a line above the alignment. NCBI accession numbers
of species indicated are as follows: Culex quinquefasciatusDOP2 = KM262648; Aedes aegypti
DOP2 = JN043503; Anopheles gambiaeDOP2 = ABKP02003382 and ABKP02020596; Phleboto-
mus papatasiDOP2 = AJVK01013962 and AJVK01013961; Glossina morsitans
DOP2 = CCAG010002977. Sequences were assembled frommultiple scaffolds for An. gambiae
and P. papatasi in order to obtain complete sequences including all three putative exons.
(TIF)
S3 Fig. Concentration response curves for C. quinquefasciatus () and Ae. aegypti (●) show-
ing percent larval mortality at 24 h post exposure to DOP2 antagonists. Each data point rep-
resents mean ± SEM (n 3 independent experiments).
(TIFF)
S4 Fig. Concentration response curves for C. quinquefasciatus () and Ae. aegypti (●) show-
ing percent larval mortality at 48 h post exposure to DOP2 antagonists. Each data point rep-
resents mean ± SEM (n 3 independent experiments).
(TIFF)
S5 Fig. Images of sublethal phenotypes observed in C. quinquefasciatus and Ae. aegypti lar-
vae following exposure to DAR antagonists. Representative examples of (A) normal (water
only control, 72 h exposure) (B) attached exuvia (arrow) (50 μM chlorprothixene, 24 h expo-
sure) and (C) shortened (100 μM chlorpromazine, 72 h exposure) phenotypes in L4 C. quin-
quefasciatus and (D) normal (water only control, 72 h exposure), (E) attached exuvia (arrow)
(400 μM chlorpromazine, 72 h exposure), and (F) shortened (50 μMmethiothepin, 72 h expo-
sure) phenotypes in L4 Ae. aegypti.
(TIF)
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